Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Update

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 3,050,000 shares, a decrease of 7.3% from the January 15th total of 3,290,000 shares. Currently, 3.4% of the shares of the company are short sold. Based on an average daily volume of 678,600 shares, the short-interest ratio is presently 4.5 days.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $15.29, for a total transaction of $91,740.00. Following the transaction, the general counsel now owns 118,265 shares in the company, valued at $1,808,271.85. This represents a 4.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CTO Tia L. Bush sold 17,813 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $18.00, for a total transaction of $320,634.00. Following the transaction, the chief technology officer now owns 147,615 shares in the company, valued at approximately $2,657,070. The trade was a 10.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 456,981 shares of company stock worth $7,814,333 in the last quarter. Corporate insiders own 11.59% of the company's stock.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its position in Centessa Pharmaceuticals by 14.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock valued at $89,854,000 after buying an additional 685,371 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock valued at $85,744,000 after buying an additional 924,027 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Centessa Pharmaceuticals by 279.2% during the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock valued at $82,218,000 after acquiring an additional 3,614,623 shares during the last quarter. Farallon Capital Management LLC raised its stake in shares of Centessa Pharmaceuticals by 24.3% during the fourth quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company's stock valued at $58,603,000 after acquiring an additional 684,391 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of Centessa Pharmaceuticals by 26.2% during the fourth quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock valued at $57,396,000 after acquiring an additional 710,936 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on CNTA shares. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating on the stock. Guggenheim reiterated a "buy" rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $25.83.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock traded down $0.12 during mid-day trading on Friday, reaching $16.63. The company had a trading volume of 590,410 shares, compared to its average volume of 787,544. Centessa Pharmaceuticals has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.19 billion, a P/E ratio of -10.87 and a beta of 1.53. The business has a fifty day simple moving average of $16.71 and a 200 day simple moving average of $15.79.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.